A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety
Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype.
Gespeichert in:
| Veröffentlicht in: | Vaccine 2015-01, Vol.33 (2), p.396-402 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 402 |
|---|---|
| container_issue | 2 |
| container_start_page | 396 |
| container_title | Vaccine |
| container_volume | 33 |
| creator | Francis, James N Bunce, Campbell J Horlock, Claire Watson, Jeannette M Warrington, Steven J Georges, Bertrand Brown, Carlton B |
| description | Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype. |
| doi_str_mv | 10.1016/j.vaccine.2014.06.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1642620693</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X14007956</els_id><sourcerecordid>1642620693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c598t-6882e7e597b4ad6b68439d6475bd04b76d364603dee8bc8fe55535a73a11409e3</originalsourceid><addsrcrecordid>eNqNkk2LFDEQhoMo7rj6E5SAFw92m-_ueFgZFr9gwYMK3kI6qZaMPek26R4Yf71pZlZhL3pJQvHUW6l6C6GnlNSUUPVqVx-scyFCzQgVNVE1Ieoe2tC24RWTtL2PNoQpUQlKvl2gRznvCCGSU_0QXTChWdtoskHLFsfxAAOeYJqDh6qzGTyebKxC7IcF4i-Lt_hc63V5-nHpBsDdEKJ_iZONftyHNceVSHB2wHMK5Rx7HPb7JY7foYTDfMQFxdn2MB8fowe9HTI8Od-X6Ou7t1-uP1Q3n95_vN7eVE7qdq5U2zJoQOqmE9arTrWCa69EIztPRNcoz5VQhHuAtnNtD1JKLm3DLaWCaOCX6MVJd0rjzwXybMpXHQyDjTAu2VAlmGJEaf4fKNdCK92wgj6_g-7GJcXSyCoouVKNXil5olwac07QmymFvU1HQ4lZLTQ7cx6rWS00RJliYcl7dlZfuj34P1m3nhXgzQmAMrlDgGSyCxAd-JDAzcaP4Z8lru4o3Hr3A46Q_3ZjMjPEfF73aF2jMlTSaKn4b_Zhw1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645366792</pqid></control><display><type>article</type><title>A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Francis, James N ; Bunce, Campbell J ; Horlock, Claire ; Watson, Jeannette M ; Warrington, Steven J ; Georges, Bertrand ; Brown, Carlton B</creator><creatorcontrib>Francis, James N ; Bunce, Campbell J ; Horlock, Claire ; Watson, Jeannette M ; Warrington, Steven J ; Georges, Bertrand ; Brown, Carlton B</creatorcontrib><description>Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.06.006</identifier><identifier>PMID: 24928790</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Allergy and Immunology ; Antibodies, Viral - immunology ; CD4-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - immunology ; Clinical trials ; Cross Reactions ; Cytokines ; Cytotoxicity ; Double-Blind Method ; Enzyme-Linked Immunospot Assay ; Epitopes, T-Lymphocyte - immunology ; Flow Cytometry ; Fluoropeptides ; Humans ; Immune response ; Immunogenicity ; Influenza ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - adverse effects ; Influenza Vaccines - immunology ; Influenza, Human - prevention & control ; Interferon-gamma - biosynthesis ; Interferon-gamma - immunology ; Leukocytes, Mononuclear - immunology ; Lymphocytes ; Male ; Middle Aged ; Pandemics ; Peptides ; Perfluorocarbons ; Safety ; Studies ; T cells ; T-Lymphocytes - immunology ; Vaccination ; Vaccine ; Vaccines ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - adverse effects ; Vaccines, Subunit - immunology ; Young Adult</subject><ispartof>Vaccine, 2015-01, Vol.33 (2), p.396-402</ispartof><rights>The Authors</rights><rights>2014 The Authors</rights><rights>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 3, 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c598t-6882e7e597b4ad6b68439d6475bd04b76d364603dee8bc8fe55535a73a11409e3</citedby><cites>FETCH-LOGICAL-c598t-6882e7e597b4ad6b68439d6475bd04b76d364603dee8bc8fe55535a73a11409e3</cites><orcidid>0000-0003-1602-4536</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X14007956$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24928790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Francis, James N</creatorcontrib><creatorcontrib>Bunce, Campbell J</creatorcontrib><creatorcontrib>Horlock, Claire</creatorcontrib><creatorcontrib>Watson, Jeannette M</creatorcontrib><creatorcontrib>Warrington, Steven J</creatorcontrib><creatorcontrib>Georges, Bertrand</creatorcontrib><creatorcontrib>Brown, Carlton B</creatorcontrib><title>A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype.</description><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Antibodies, Viral - immunology</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Clinical trials</subject><subject>Cross Reactions</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Double-Blind Method</subject><subject>Enzyme-Linked Immunospot Assay</subject><subject>Epitopes, T-Lymphocyte - immunology</subject><subject>Flow Cytometry</subject><subject>Fluoropeptides</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunogenicity</subject><subject>Influenza</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - adverse effects</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza, Human - prevention & control</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Interferon-gamma - immunology</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>Peptides</subject><subject>Perfluorocarbons</subject><subject>Safety</subject><subject>Studies</subject><subject>T cells</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - adverse effects</subject><subject>Vaccines, Subunit - immunology</subject><subject>Young Adult</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkk2LFDEQhoMo7rj6E5SAFw92m-_ueFgZFr9gwYMK3kI6qZaMPek26R4Yf71pZlZhL3pJQvHUW6l6C6GnlNSUUPVqVx-scyFCzQgVNVE1Ieoe2tC24RWTtL2PNoQpUQlKvl2gRznvCCGSU_0QXTChWdtoskHLFsfxAAOeYJqDh6qzGTyebKxC7IcF4i-Lt_hc63V5-nHpBsDdEKJ_iZONftyHNceVSHB2wHMK5Rx7HPb7JY7foYTDfMQFxdn2MB8fowe9HTI8Od-X6Ou7t1-uP1Q3n95_vN7eVE7qdq5U2zJoQOqmE9arTrWCa69EIztPRNcoz5VQhHuAtnNtD1JKLm3DLaWCaOCX6MVJd0rjzwXybMpXHQyDjTAu2VAlmGJEaf4fKNdCK92wgj6_g-7GJcXSyCoouVKNXil5olwac07QmymFvU1HQ4lZLTQ7cx6rWS00RJliYcl7dlZfuj34P1m3nhXgzQmAMrlDgGSyCxAd-JDAzcaP4Z8lru4o3Hr3A46Q_3ZjMjPEfF73aF2jMlTSaKn4b_Zhw1g</recordid><startdate>20150103</startdate><enddate>20150103</enddate><creator>Francis, James N</creator><creator>Bunce, Campbell J</creator><creator>Horlock, Claire</creator><creator>Watson, Jeannette M</creator><creator>Warrington, Steven J</creator><creator>Georges, Bertrand</creator><creator>Brown, Carlton B</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U2</scope><orcidid>https://orcid.org/0000-0003-1602-4536</orcidid></search><sort><creationdate>20150103</creationdate><title>A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety</title><author>Francis, James N ; Bunce, Campbell J ; Horlock, Claire ; Watson, Jeannette M ; Warrington, Steven J ; Georges, Bertrand ; Brown, Carlton B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c598t-6882e7e597b4ad6b68439d6475bd04b76d364603dee8bc8fe55535a73a11409e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Antibodies, Viral - immunology</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Clinical trials</topic><topic>Cross Reactions</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Double-Blind Method</topic><topic>Enzyme-Linked Immunospot Assay</topic><topic>Epitopes, T-Lymphocyte - immunology</topic><topic>Flow Cytometry</topic><topic>Fluoropeptides</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunogenicity</topic><topic>Influenza</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - adverse effects</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza, Human - prevention & control</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Interferon-gamma - immunology</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>Peptides</topic><topic>Perfluorocarbons</topic><topic>Safety</topic><topic>Studies</topic><topic>T cells</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - adverse effects</topic><topic>Vaccines, Subunit - immunology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Francis, James N</creatorcontrib><creatorcontrib>Bunce, Campbell J</creatorcontrib><creatorcontrib>Horlock, Claire</creatorcontrib><creatorcontrib>Watson, Jeannette M</creatorcontrib><creatorcontrib>Warrington, Steven J</creatorcontrib><creatorcontrib>Georges, Bertrand</creatorcontrib><creatorcontrib>Brown, Carlton B</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Francis, James N</au><au>Bunce, Campbell J</au><au>Horlock, Claire</au><au>Watson, Jeannette M</au><au>Warrington, Steven J</au><au>Georges, Bertrand</au><au>Brown, Carlton B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2015-01-03</date><risdate>2015</risdate><volume>33</volume><issue>2</issue><spage>396</spage><epage>402</epage><pages>396-402</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>24928790</pmid><doi>10.1016/j.vaccine.2014.06.006</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-1602-4536</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2015-01, Vol.33 (2), p.396-402 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1642620693 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Allergy and Immunology Antibodies, Viral - immunology CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - immunology Clinical trials Cross Reactions Cytokines Cytotoxicity Double-Blind Method Enzyme-Linked Immunospot Assay Epitopes, T-Lymphocyte - immunology Flow Cytometry Fluoropeptides Humans Immune response Immunogenicity Influenza Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Influenza Vaccines - immunology Influenza, Human - prevention & control Interferon-gamma - biosynthesis Interferon-gamma - immunology Leukocytes, Mononuclear - immunology Lymphocytes Male Middle Aged Pandemics Peptides Perfluorocarbons Safety Studies T cells T-Lymphocytes - immunology Vaccination Vaccine Vaccines Vaccines, Subunit - administration & dosage Vaccines, Subunit - adverse effects Vaccines, Subunit - immunology Young Adult |
| title | A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T22%3A06%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20novel%20peptide-based%20pan-influenza%20A%20vaccine:%20A%20double%20blind,%20randomised%20clinical%20trial%20of%20immunogenicity%20and%20safety&rft.jtitle=Vaccine&rft.au=Francis,%20James%20N&rft.date=2015-01-03&rft.volume=33&rft.issue=2&rft.spage=396&rft.epage=402&rft.pages=396-402&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2014.06.006&rft_dat=%3Cproquest_cross%3E1642620693%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645366792&rft_id=info:pmid/24928790&rft_els_id=S0264410X14007956&rfr_iscdi=true |